评估 VT3989 在转移性实体瘤患者中的研究,该肿瘤富含 NF2 基因突变的肿瘤
评估 VT3989 在难治性局部晚期或转移性实体瘤患者中的安全性、耐受性和 PK 的第 1 期、多中心、开放标签研究,富含 NF2 基因突变的肿瘤
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
研究概览
地位
条件
详细说明
Dose escalation (Part 1) will employ a traditional 3 + 3 design to assess safety of VT3989 in patients with metastatic solid tumors or mesothelioma. The 3 + 3 design will be implemented until the MTD or recommended phase 2 dose(s) and schedule(s) are determined. The MTD is defined as the highest dose level at which < 33% of patients experience a dose limiting toxicity (DLT) during the first cycle of the study (Cycle 1).
Dose Expansion (Part 2) will further evaluate the safety and assess preliminary antitumor activity at the recommended phase 2 dose(s) and schedule(s) with up to 6 cohorts. Expansion cohorts 1 and 2 will enroll patients with mesothelioma of any site origin with or without NF2 mutations. Expansion cohort 3 will enroll non-pleural mesothelioma patients. Expansion cohort 4 will enroll solid tumor patients with clearly inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements. Cohort 5 will enroll pleural mesothelioma patients.
Combination part (Part 3) includes three cohorts. Cohort A will enroll mesothelioma patients who will receive VT3989 in combination with immunotherapy (nivolumab plus ipilimumab). Cohort B will enroll NSCLC patients whose tumors have exon 19 deletion or exon 21 L858R mutation and will receive VT3989 in combination with targeted therapy (Osimertinib). Cohort C will enroll pleural mesothelioma patients who will receive VT3989 in combination with chemotherapy (pemetrexed plus carboplatin).
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Heather Fritz
- 电话号码:650-627-7437
- 邮箱:hfritz@inclin.com
研究联系人备份
- 姓名:Neelesh Sharma, MD
- 电话号码:732-476-4978
- 邮箱:nsharma@vivacetherapeutics.com
学习地点
-
-
Victoria
-
Clayton、Victoria、澳大利亚、3168
- 招聘中
- Monash Health
-
接触:
- Monash ONC Early Phase Team
- 电话号码:+61 0474 769 510
- 邮箱:earlyphase.oncresearch@monashhealth.org
-
Melbourne、Victoria、澳大利亚、3000
- 招聘中
- Peter MacCullum Cancer Centre
-
接触:
- PCCTU Early Phase Team
- 电话号码:+61 3 8559 5000
- 邮箱:Pcctu.edd@petermac.org
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚、6009
- 终止
- Linear Clinical Research
-
-
-
-
California
-
San Francisco、California、美国、94158
- 招聘中
- UCSF Helen Diller Family Comprehensive Cancer Center
-
接触:
- Lisa Tan
- 电话号码:415-866-7866
- 邮箱:Lisa.Tan@ucsf.edu
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago Medical Center
-
接触:
- University of Chicago Clinical Trials
- 电话号码:855-702-8222
- 邮箱:cancerclinicaltrials@bsd.uchicago.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Massachusetts General Hospital
-
接触:
- Massachusetts General Hospital Oncology - Main Line
- 电话号码:617-724-1134
- 邮箱:research@massgeneralbrigham.org
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute
-
接触:
- David Kwiatkowski, MD, PhD
- 电话号码:877-442-3324
- 邮箱:dfcitopreferrals@dfci.harvard.edu
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- 招聘中
- M Health Fairview University of Minnesota Medical Center
-
接触:
- Robert Kratzke, MD
- 电话号码:612-273-8383
- 邮箱:kratz003@umn.edu
-
-
New York
-
New York、New York、美国、10065
- 招聘中
- Memorial Sloan Kettering Cancer Center
-
接触:
- Michael Offin, MD
- 电话号码:646-608-3763
- 邮箱:offinm@mskcc.org
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- MD Anderson Cancer Center
-
接触:
- Timothy Yap, MD
- 电话号码:713-563-1784
- 邮箱:Tyap@mdanderson.org
-
接触:
-
San Antonio、Texas、美国、78229
- 招聘中
- NEXT Oncology
-
接触:
- Jordan Georg, Patient Care Coordinator Lead
- 电话号码:210-580-9539
- 邮箱:Jgeorg@nextoncology.com
-
-
Virginia
-
Arlington、Virginia、美国、22201
- 招聘中
- Virginia Cancer Specialists, PC
-
接触:
- Alexander Spira, MD
- 电话号码:703-783-4510
- 邮箱:aspira@nextoncology.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy.
- Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.
- Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy.
- Part 1: Evaluable or measurable disease per RECIST v1.1 or mRECIST
- Part 2 and 3: Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
- ECOG: 0-1.
- Adequate organ functions, including the liver, kidneys, and hematopoietic system.
Exclusion Criteria:
- Active brain metastases or primary CNS (central nervous system) tumors.
- History of leptomeningeal metastases
- Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- Known HIV positive or active Hepatitis B or Hepatitis C
- Clinically significant cardiovascular disease and prior exposure to cardiotoxic agents.
- Corrected QT (QTcF) interval > 470 msec (using Fridericia's correction formula).
- Additional active malignancy that may confound the assessment of the study endpoints
- Women who are pregnant or breastfeeding
- Unwilling or unable to use highly effective contraceptive measures.
- Prior treatment with TEAD inhibitor, except for EHE patients.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:VT3989 Dose Escalation [Not Recruiting]
VT3989 dosed orally in 21 or 28 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase |
25, 50, 100, 150 or 200 mg for oral administration. |
|
实验性的:Dose Expansion [Not Recruiting]
VT3989 dosed in 21 or 28 day cycles in patients with refractory metastatic solid tumors or mesothelioma. |
25, 50, 100, 150 or 200 mg for oral administration. |
|
实验性的:Combination [Recruiting]
For Cohort A and B, VT3989 dosed in 28 day cycles in patients with metastatic solid tumors or mesothelioma, in combination with immunotherapy (nivolumab/ipilimumab) or targeted therapy (osimertinib). For Cohort C, VT3989 dosed in 21 day cycles in patients with mesothelioma in combination with chemotherapy (pemetrexed+carboplatin) for 4-6 cycles, then continuing VT3989 as monotherapy on 28-day cycle. |
25, 50, 100, 150 or 200 mg for oral administration. Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion 40 or 80 mg tablets for oral administration Pemetrexed infusion: 500 mg/m2 intravenous infusion Carboplatin infusion: AUC 5.0 intravenous infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of Dose Limiting Toxicity
大体时间:over the first 21 days of dosing
|
Incidence of Adverse and Serious Adverse Events |
over the first 21 days of dosing
|
|
Occurrence of General Toxicity
大体时间:through study completion, an average of 30 months
|
Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety evaluations |
through study completion, an average of 30 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Tumor Response
大体时间:through study completion, an average of 30 months
|
Determined by RECIST v1.1 or modified RECIST v1.1 |
through study completion, an average of 30 months
|
|
Pharmacokinetic Evaluation - Cmax
大体时间:for first 6 cycles
|
Peak plasma concentration of VT3989 |
for first 6 cycles
|
|
Pharmacokinetic Evaluation - Tmax
大体时间:for first 6 cycles
|
Time to reach peak plasma concentration of VT3989 |
for first 6 cycles
|
|
Pharmacokinetic Evaluation - Half-life
大体时间:for first 6 cycles
|
Time required for the plasma concentration of VT3989 to reduce by half after reaching peak |
for first 6 cycles
|
|
Overall survival
大体时间:At 6, 12, 18 and 24 months
|
The overall survival of the enrolled patients from starting VT3989 treatment |
At 6, 12, 18 and 24 months
|
|
Progression free survival
大体时间:At 6, 12, 18 and 24 months
|
The progression free survival of the enrolled patients from starting VT3989 treatment |
At 6, 12, 18 and 24 months
|
|
Quality of life assessment (Part 2, expansion cohort 3, 4, and 5)
大体时间:Through study completion, an average of 30 months
|
Assessing the Quality of life changes via patient reported outcomes |
Through study completion, an average of 30 months
|
合作者和调查者
调查人员
- 研究主任:Neelesh Sharma, MD、Vivace Therapeutics
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- VT3989-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.